Skip to content

Cornutopia: A short story and what it can tell us about ethnic minority views on psychedelic research, and the potential impact on clinical outcomes

Caroline Hayes

Journal of Psychedelic Studies May 13, 2025 Peer reviewed DOI: 10.1556/2054.2025.00412 via OpenAlex

Summary

The fictional story 'Cornutopia' by Irenosen Okojie critiques the enthusiasm for psychedelic research through the negative experience of its protagonist, Amel Dyani, a young Black woman in a clinical trial. Her journey highlights issues like bias and patient vulnerability, contrasting with the generally positive narratives about psychedelic therapy. The narrative raises concerns about mistrust in healthcare and suggests that racial factors may influence clinical outcomes, emphasizing the need for improved inclusion practices in future research.

Study at a glance

Population a fictional character participating in a psychedelic clinical trial
Key finding The protagonist's negative experience in a psychedelic trial suggests potential differences in clinical outcomes between racial groups and highlights the need for greater awareness of barriers to inclusion for ethnic minorities.

Abstract

Abstract The fictional story, Cornutopia , by British-Nigerian author Irenosen Okojie, offers a critical outsider's perspective on the enthusiasm surrounding psychedelic research, notably from outside the small world of psychedelic research. The protagonist, Amel Dyani, a young Black woman, participates in a psychedelic clinical trial but has a negative experience. This article aims to analyse the narrative to see what the sector can learn about minority views on psychedelic research, and what we can do to improve. Amel's fictional experience touches on a number of issues within psychedelic clinical trials, such as bias and the vulnerability of patients under the influence of psychedelics. The protagonist comes away from the experience in a seemingly worse condition than when she started, which deviates from the often overwhelmingly positive coverage of the potential of psychedelic-assisted therapy. A theme of mistrust of healthcare professionals permeates the prose. This is significant in light of calls for greater diversity in psychedelic clinical trials, and the hypothesised role that race may have on the set and setting of a psychedelic experience. We must consider whether this means there is potential for there to be differences in clinical outcomes between racial groups for psychedelic-assisted therapy. On the basis of themes raised in the story recommendations are made to inform future practice, such as improving researchers' awareness of barriers to inclusion for those from ethnic minority backgrounds as well as targeted attention towards the possibility of racial differences in therapy outcomes.

Tags

Comments

No comments yet.

Log in to comment